REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters-Reference-Cited by-同舟云学术

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

Published:2020-11-27 Issue:6520 Volume:370 Page:1110-1115
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Baum Alina¹^ORCID,Ajithdoss Dharani¹^ORCID,Copin Richard¹,Zhou Anbo¹,Lanza Kathryn¹,Negron Nicole¹,Ni Min¹,Wei Yi¹,Mohammadi Kusha¹^ORCID,Musser Bret¹^ORCID,Atwal Gurinder S.¹,Oyejide Adelekan¹^ORCID,Goez-Gazi Yenny²,Dutton John²^ORCID,Clemmons Elizabeth²^ORCID,Staples Hilary M.²,Bartley Carmen²^ORCID,Klaffke Benjamin²,Alfson Kendra²^ORCID,Gazi Michal²,Gonzalez Olga²^ORCID,Dick Edward²^ORCID,Carrion Ricardo²^ORCID,Pessaint Laurent³^ORCID,Porto Maciel³,Cook Anthony³,Brown Renita³,Ali Vaneesha³^ORCID,Greenhouse Jack³^ORCID,Taylor Tammy³^ORCID,Andersen Hanne³^ORCID,Lewis Mark G.³^ORCID,Stahl Neil¹^ORCID,Murphy Andrew J.¹^ORCID,Yancopoulos George D.¹,Kyratsous Christos A.¹^ORCID

Affiliation:

1. Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA.

2. Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX 78245, USA.

3. BIOQUAL, Rockville, MD 20850, USA.

Abstract

A beneficial cocktail Since the start of the coronavirus disease 2019 (COVID-19) pandemic, considerable effort has gone into generating and characterizing neutralizing antibodies that could be used as therapeutics. Studies in humanized mice and convalescent humans led to the development of a cocktail of two potent antibodies that simultaneously bind to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and prevent the virus from entering host cells. Baum et al. evaluated the efficacy of this cocktail, REGN-COV2, in rhesus macaques, which may model mild disease, and in golden hamsters, which present more severe symptoms. The antibody cocktail provided benefits in both models when administered either prophylactically or therapeutically and is currently in clinical trials. Science , this issue p. 1110

Funder

Biomedical Advanced Research and Development Authority

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference37 articles.

1. The race is on for antibodies that stop the new coronavirus

2. Human neutralizing antibodies elicited by SARS-CoV-2 infection

3. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

4. A human monoclonal antibody blocking SARS-CoV-2 infection

5. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells

Cited by 477 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evidence that the SARS-CoV-2 S protein undergoes a conformational change at the Golgi complex that leads to the formation of virus neutralising antibody binding epitopes in the S1 protein subunit;Virology;2024-10

2. Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control;Signal Transduction and Targeted Therapy;2024-09-11

3. Inhalable dry powders of a monoclonal antibody against SARS-CoV-2 virus made by thin-film freeze-drying;International Journal of Pharmaceutics;2024-09

4. Deciphering Fc-effector functions against SARS-CoV-2;Trends in Microbiology;2024-08

5. Genetic barrier to resistance: a critical parameter for efficacy of neutralizing monoclonal antibodies against SARS-CoV-2 in a nonhuman primate model;Journal of Virology;2024-07-23